转移性去势抵抗性前列腺癌：取得重大进展但引发更多问题
Metastatic Castration-resistant Prostate Cancer: Major Progress Leading to Even More Questions.
作者信息
Mottet Nicolas
机构信息
Department of Urology, Hopital Nord, Saint-Étienne, France.
出版信息
Eur Urol Focus. 2016 Dec;2(5):562-564. doi: 10.1016/j.euf.2016.10.006. Epub 2016 Nov 14.
PMID:28723523
Abstract
Treatment of metastatic castration-resistant prostate cancer is complex and we are facing more questions with major practical impact with the available effective drugs. Treatment optimization requires that all clinical partners work together. Survival is linked to the number of regimen used. The androgen pathway is key, while chemotherapy is the other major tool.
摘要
转移性去势抵抗性前列腺癌的治疗很复杂，并且随着现有有效药物的出现，我们面临着更多具有重大实际影响的问题。治疗优化需要所有临床合作伙伴共同努力。生存期与使用的治疗方案数量相关。雄激素途径是关键，而化疗是另一个主要手段。
Zotero 插件